title: Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.
abstract: OBJECTIVE
  No therapy has been shown to reliably prevent the evolution of postoperative recurrence of Crohn's disease. The aim of the current trial was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for the prevention of clinical, endoscopic, and radiographic recurrence of Crohn's disease after resection and ileocolic anastomosis.
  
  
  METHODS
  Five centers randomized 131 patients to receive 6-MP (50 mg), mesalamine (3 g), or placebo daily in a double-blind, double-dummy trial. Patients had clinical assessments at 7 weeks and then every 3 months; colonoscopy at 6, 12, and 24 months; and small bowel series at 12 and 24 months. End points were clinical, endoscopic, and radiographic recurrence rates at 24 months.
  
  
  RESULTS
  Clinical recurrence rates (intent to treat) by life-table analysis at 24 months were 50% (95% confidence interval [CI], 34%-68%), 58% (95% CI, 41%-75%), and 77% (95% CI, 61%-91%) in patients receiving 6-MP, mesalamine, and placebo, respectively. Endoscopic recurrence rates were 43% (95% CI, 28%-63%), 63% (95% CI, 47%-79%), and 64% (95% CI, 46%-81%), and radiographic recurrence rates were 33% (95% CI, 19%-54%), 46% (95% CI, 29%-66%), and 49% (95% CI, 30%-72%), respectively. 6-MP was more effective than placebo ( P < 0.05) at preventing clinical and endoscopic recurrence over 2 years. Patient withdrawals resulted in 69% of the study population evaluable for the clinical recurrence end point.
  
  
  CONCLUSIONS
  6-MP, 50 mg daily, was more effective than placebo at preventing postoperative recurrence of Crohn's disease and should be considered as a maintenance therapy after ileocolic resection.
authors.affiliation: Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA. shanauer@medicine.bsd.uchicago.edu
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Hanauer
authors.forename: Burton I
authors.initials: BI
authors.lastname: Korelitz
authors.forename: Paul
authors.initials: P
authors.lastname: Rutgeerts
authors.forename: Mark A
authors.initials: MA
authors.lastname: Peppercorn
authors.forename: Ronald A
authors.initials: RA
authors.lastname: Thisted
authors.forename: Russell D
authors.initials: RD
authors.lastname: Cohen
authors.forename: Daniel H
authors.initials: DH
authors.lastname: Present
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D003424:Crohn Disease / Q000517:prevention & control* / Q000601:surgery; D013505:Digestive System Surgical Procedures / Q000379:methods; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage*; D019804:Mesalamine / Q000008:administration & dosage*; D008875:Middle Aged; D011184:Postoperative Period; D012074:Remission Induction; D055502:Secondary Prevention; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents; D019804:Mesalamine; D015122:Mercaptopurine